All | LR+RT- | LR-RT- | |
---|---|---|---|
n = 22 | n = 44 | ||
Time to local recurrence, months | |||
Median | 35 | - | |
Range | 11–96 | - | |
Follow-up, months | |||
Median | - | 84 | |
Range | - | 21–166 | |
Tamoxifen | 2 | 4 | |
Chemotherapy | 1 | 1 | |
Tamoxifen and chemotherapy | 1 | 0 | |
No adjuvant treatment | 18 | 39 | |
Inclusion 1 and 2 | Inclusion 1 | Inclusion 1 | Inclusion 2 |
Menopause | |||
Pre | 9 | 3 | 4 |
Post | 13 | 30 | 2 |
Not available | 0 | 0 | 5 |
Age at operation, years | |||
Median | 53 | 61 | 49 |
Range | 44–73 | 45–70 | 40–62 |
Size, millimeters | |||
Median | 15 | 13 | 16 |
Range | 7–30 | 6–40 | 10–26 |
Not available | 0 | 0 | 0 |
Grade | |||
1 | 4 | 13 | 5 |
2 | 10 | 9 | 3 |
3 | 5 | 8 | 3 |
Not available | 3 | 3 | 0 |
Estrogen receptor | |||
Positive | 14 | 27 | 11 |
Negative | 8 | 6 | 0 |
Progesterone receptor | |||
Positive | 15 | 17 | 11 |
Negative | 7 | 14 | 0 |
Not available | 0 | 2 | 0 |
Health care region | |||
South | 9 | 21 | 11 |
West | 13 | 10 | 0 |
South-East | 0 | 0 | 0 |
Stockholm | 0 | 2 | 0 |